Editas Medicine, Inc., a leading genome editing company, announced it has exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics that will enhance and broaden the range of medicines the company can develop. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR genome editing system.
 
The WilmerHale deal team included Partners Steven Barrett and Rosemary Reilly; Counsel Jeffries Oliver-Li, Associates Hilary Baker-Jennings and Brett Bromann; and Attorney Heidi Treiber.
 
Read the press release published by Editas Medicine for more information.